PCRX Stock Up on Patent Settlement. Shares of Pacira Biosciences gained after the company announced settlement agreement with Fresenius, Jiangsu Hengrui Pharmaceuticals and eVenus ...

Pacira Biosciences leads in non-opioid pain relief with Exparel & upcoming knee osteoarthritis therapy. Click here to read my ...

Pacira BioSciences settles US patent litigations with three companies for Exparel: Brisbane, California Wednesday, April 9, 2025, 15:00 Hrs [IST] Pacira BioSciences, Inc, the indu ...

Pharmaceutical stocks fell across Asian markets after U.S. President Trump said he plans to impose a "major" tariff on all pharmaceutical imports.

"China's biotechnology sector thrives on a dual engine — Beijing's constellation of famous medical universities training ...

Under the terms of the settlement, Pacira has agreed to provide Fresenius with a license to its patents required to ...

HIES and HRC had announced partnering to optimise compressed air system efficiency for HRC’s operations. The reinforced ...

Pacira BioSciences stock rises as it settles Exparel patent litigation with several generic players protecting the drug's exclusivity in the United States at least until 2030.

Pacira settles Exparel patent cases, grants Fresenius phased license for generic sales beginning in 2030, with full access no ...

Pacira BioSciences (PCRX) stock soars 15% after resolving a patent dispute on non-opioid pain therapy, Exparel with a unit of ...

Shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) leaped 15% following the announcement of a settlement in U.S. patent litigation concerning its flagship product, EXPAREL. The agreement effectively ...

BioSciences announced that it has settled its litigations with Fresenius Kabi USA, LLC (Fresenius), Jiangsu Hengrui ...